Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19062812 | 0.95 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C19NOS3NOS1 | |
| SCHEMBL15628463 | 0.95 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C19NOS3NOS1 | |
| SCHEMBL20026332 | 0.86 | HRH3 (0.44) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20026088 | 0.81 | PIK3CA (0.39) | MKNK1MKNK2 | |
| SCHEMBL19062432 | 0.81 | PIK3CA (0.39) | MKNK1MKNK2 | |
| SCHEMBL15628455 | 0.81 | LOXL2 (0.36) | CYP1A2CYP2D6CYP2C19NOS3NOS1 | |
| SCHEMBL19063250 | 0.81 | TSHR (0.39) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20026377 | 0.80 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20026328 | 0.79 | CYP1A2 (0.36) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17490437 | 0.79 | ATM (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | ERN1 2716/4885KIF11 2737/4885ROCK1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.